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Background: Hematological abnormalities are common in HIV positive patients. Of these, thrombocytopenia is a
known complication which has been associated with progression of disease. However, its magnitude and
associated factors in HAART naive HIV positive patients is not known in Ethiopia. Therefore, the aim of this study
was to determine the prevalence and associated factors of thrombocytopenia in HAART naïve HIV positive patients.
Methods: A retrospective study was carried out among HAART naive HIV positive patients at Gondar University
Hospital, Northwest Ethiopia, from September 2011 through August 2012. Socio-demographic variables and
immunohematological (platelets and CD4+ T cells) values were carefully reviewed from medical records.
Associated factors and outcomes were assessed using logistic regression.
Results: A total of 390 HAART naive HIV positive patients with a mean age of 33.65 years and a range of
18–70 years were reviewed. The overall prevalence of thrombocytopenia was 23(5.9%). The mean CD4 count
was 288 ± 188.2 cells/μL. HIV patients whose age ≥ 50 years old were 2.5 times more likely to have
thrombocytopenia and those patients whose CD4 count < 350 were 2.6 times more likely to have
thrombocytopenia than HIV patients whose CD4 count ≥500. However, CD4 count was not statistically
associated with prevalence of thrombocytopenia (P > 0.05).
Conclusion: As CD4 counts of HIV patients decreasing, they have more likely to have thrombocytopenia.
Therefore, early diagnosis and treatment of thrombocytopenia in these patients are necessary.
Keywords: Thrombocytopenia, HIV, HAART naive, CD4 countBackground
Human immunodeficiency virus (HIV) is a retrovirus that
infects cells of the immune system, destroying or impairing
their function, which leads to the occurrence of opportun-
istic infections and tumors [1]. Though the malfunction of
the immune system and the decrease in the number and
activity of CD4+ T cells signify the hallmark of HIV infec-
tion, it is notable that HIV can also impede with other cell
lineages and tissues [2,3]. In addition to progressive reduc-
tion of CD4+ T cells, peripheral blood cytopenias, such as* Correspondence: get29f@gmail.com
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distribution, and reproduction in any mediumanaemia, neutropenia and thrombocytopenia, happen in
most patients with AIDS [4,5].
Peripheral blood cytopenias have been showed even
in the absence of chemotherapeutic treatment or oppor-
tunistic infections and tumours, signifying that HIV in-
fection may be directly associated with the induction of
these hematological abnormalities [6]. Intriguingly, identi-
fied thrombocytopenia can signify the first clinical mani-
festation in otherwise asymptomatic HIV positive patients
[7] while neutropenia and anaemia are more common in
the late stages of HIV disease [8].
Thrombocytopenia is characterized by platelet counts
below 125 × 103/mm3, and also frequently occurs in HIV-
infected patients [9-11]. Its pathogenesis has not yet beenentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Socio-demographic characteristics of HAART
naive HIV positive patients at Gondar university hospital,
northwest Ethiopia, 2013
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are increased platelet destruction, either caused by the non-
specific deposition of circulating immune complexes on
platelets or by the presence of specific anti-platelet anti-
bodies, as well as direct infection of megakaryocytes by
HIV with a resulting ineffective in platelet production[12].
Incidence of thrombocytopenia is around 40% of HIV-
infected persons, and in approximately 10% of the patients,
it may be the first sign of AIDS [13]. This haematological
disorder may represent the first manifestation of HIV infec-
tion and it may progress over time and lead to severe bleed-
ing [14]. Mature Megakaryoctes (MKs) can be infected by
HIV through binding the CD4 receptor [15], and HIV ge-
nomes have been detected in MKs purified from bone mar-
row (BM) of HIV-positive patients [16].
The infection of MKs is not strain-restricted because
both R5- and X4-tropic HIV-1 strains are able to infect
MKs thus indicating that the infection may occur early in
the development of HIV infection [17]. In addition to these
direct effects of HIV on the MK cell lineage, HIV also sup-
ports chronic thrombocytopenia through autoimmune
mechanisms [14], particularly manifest in early stages of the
disease [18]. Autoimmune mechanisms are associated to
anti-HIV antibodies cross-reacting with platelet-membrane
glycoproteins, supporting the basic role of molecular mim-
icry in the induction of these antibodies [19].
Thrombocytopenia is associated with increased morbid-
ity and mortality, accelerated deterioration in CD4 counts
and accelerated progression to AIDS [20]. The incidence
of thrombocytopenia varied according to the definition of
thrombocytopenia and the characteristics of the baseline
population [21]. There is no such information for HIV-
infected individuals in Ethiopia which may help to inform
respective bodies for treatment of HIV-infected individuals
in this area. We therefore assessed the prevalence of
thrombocytopenia in HIV-infected HAART naive patients
and also tried to determine the relationship between
thrombocytopenia and CD4 cell counts in these patients.
Methods
A retrospective study was carried out among HAART naive
HIV positive patients at Gondar University Hospital,
Northwest Ethiopia, from September 2011 through August
2012. Gondar University Hospital provides HIV/AIDS in-
terventions including free diagnosis, treatment and moni-
toring. The center diagnoses new cases and monitors those
on therapy. Patients on interferon therapy, chemotherapy,
or malignancy were excluded.
Socio-demographic variables and immunohematologi-
cal (platelets and CD4+ T cells) values were carefully
reviewed retrospectively from medical records. Reviewed
laboratory data of platelets analyses were done using the
automated blood analyzer Cell-Dyn 1800 (Abott Laborator-
ies Diagnostics Division, USA) and CD4 T lymphocytecounts were done using the Becton Dickinson FACS
count. Thrombocytopenia was defined as platelets
count <125.0 × 103/mm [22,23].
SPSS version 16 statistical software was used for analysis
of the data. Descriptive statistics (minimum, maximum,
mean and standard deviation) were used for continuous
variables in the course of analysis and categorical data
were analyzed using logistic regression. A P-value of < 0.05
was considered to be statistically significant.
Ethical clearance was obtained from the Institutional
Ethical Review Board of University of Gondar and Per-
mission for data collection was also obtained from the
University Hospital.
Result
A total of 390 HAART naïve HIV positive patient results
were reviewed from their medical records. Out of these,
271 (69.5%) were females. The mean age of the patients
was 33.65 ± 9.1 years, ranging from 18–70 years. The ma-
jority of study participants 328 (84.1%) were urban resi-
dents (Table 1).
The overall prevalence of thrombocytopenia was 23
(5.9%). Platelet levels of the study participants were be-
tween 29×103 cells/μl and 653×103 cells/μl with the mean
of 258×103 ± 100.561 cells/μl. The minimum CD4 count
was 9 cells/μL, and the maximum was 1280 cells/μL. The
mean CD4 count was 288 ± 188.2 cells/μL. In this study,
majority of the thrombocytopenia cases 12 (7.3%) were
observed in the age group of 30–39 years. However, the
difference was not statistically significant. HIV patients
whose age ≥ 50 years old were 2.5 times more likely to have
Table 2 Prevalence of thrombocytopenia among HAART
naive HIV positive patients at Gondar university hospital,
northwest Ethiopia, 2013
Platelet count Frequency Percentage (%)
≥125.0 × 103/mm 367 94.1
<125.0 × 103/mm 23 5.9
Total 390 100
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350 were 2.6 times more likely to have thrombocytopenia
than HIV patients whose CD4 count ≥500 (Tables 2 and 3).
Discussion
Increasing the intricacy of HIV infection, varied
hematological manifestations can be seen, in which HIV
related thrombocytopenia is one of them [24]. We assessed
platelet counts in HAART naive HIV infected patients,
which showed that 5.9% of the sample population had
thrombocytopenia, which was in agreement with previous
studies by Denue et al.,[25], Sloand et al.,[21], Sullivan
et al.,[26], and Suresh et al., [27]. However, lower than re-
ported by Erhabor et al., [28] and Akinsegun et al.,[29].
This problem is truly a medical challenge in vulnerable
population, especially by the limited therapeutic op-
tions and the absence of intervention protocol for HIV
subjects [9].
Results from this study showed that majority of
HAART-naïve HIV positive patients were females. The fe-
male prevalence in this study confirms the World Health
Organization (WHO) report that HIV/AIDS affects females
most severely in sub-Saharan Africa [30,31]. However,
thrombocytopenia had not showed statistical significanceTable 3 Association of thrombocytopenia with related factors
university hospital, northwest Ethiopia, 2013
Variables Thrombocytopenia













Note: 1- reference group.with sex and age (p > 0.05). This was in agreement with
previous study done by Majluf-Cruz [24].
According to the present study, as immunity of a patient
decreasing, thrombocytopenia was more prevalent rather
than HIV positive patients who have relatively high CD4
count. For example, the prevalence of thrombocytopenia
was proportionally high among patients who had a CD4
lymphocyte count of ≤ 350 cells/μL and low among patients
with a CD4 count > 500 cells/μL. However, the increase in
prevalence of thrombocytopenia with decreased CD4 cell
count was not statistically significant (P >0.05). Similar find-
ings have been reported by Elisaphane et al., [32], Ira and
Bhushan [33].
To the best of our knowledge, this is the first study in
Ethiopia to determine prevalence of thrombocytopenia in
HAART-naïve HIV infected patients. However, this study
had limitations such as its retrospective nature which in-
troduces possible biases related to ascertainment, docu-
mentation and chart review. In addition, this study was
not included HIV infected patients who had on HAART.
However, the observed results may still be a good reflec-
tion of a true circumstances and this study serve as a ref-
erence for additional recommendations to improve care of
HIV infected persons and a step for further studies on the
pathophysiology of HIV associated thrombocytopenia.Conclusion
In conclusion, as CD4 counts of HIV patients decreasing,
they have more likely to have thrombocytopenia. Based on
this finding, it is recommended that physicians giving care
for HIV infected individuals should routinely investigate
and treat thrombocytopenia.among HAART naïve HIV positive patients at Gondar
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